Meeting
2016 ASCO Annual Meeting
Role of TP53 mutations in predicting response to TKI treatment in EGFR-mutated NSCLC patients.
Authors
Paola Ulivi
Biosciences Laboratory, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy
Paola Ulivi , Matteo Canale , Elisabetta Petracci , Elisa Chiadini , Claudio Dazzi , Laura Capelli , Alessandro Gamboni , Claudia Casanova , Maximilian Papi , Marita Mariotti , Nicoletta De Luigi , Marco Angelo Burgio , Vienna Ludovini , Chiara Bennati , Rita Chiari , Daniele Calistri , Lucio Crino , Dino Amadori , Angelo Delmonte
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Metastatic
Track
Lung Cancer
Sub Track
Metastatic Non–Small Cell Lung Cancer
Citation
J Clin Oncol 34, 2016 (suppl; abstr 9052)
DOI
10.1200/JCO.2016.34.15_suppl.9052
Abstract #
9052
Poster Bd #
375
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
Exon-16-skipping ERBB2 (ERBB2ΔEx16) as a novel resistance mechanism against EGFR tyrosine kinase inhibitors in non-small cell lung cancer (NSCLC).
First Author: Xin Zhao
Poster
2024 ASCO Annual Meeting
Safety and efficacy of osimertinib in patients with NSCLC and uncommon tumoral EGFR mutations: A systematic review and meta-analysis.
First Author: Jonathan N. Priantti
Poster
2021 ASCO Annual Meeting
Targeted ctDNA sequencing analysis reveals concurrent genomic alterations and its impact on TKI and immune checkpoint inhibitor therapy in advanced NSCLC from Asian population.
First Author: Wei Wu
Poster
2020 ASCO Virtual Scientific Program
Osimertinib in non-small cell lung cancer (NSCLC) with atypical EGFR activating mutations: A retrospective multicenter study.
First Author: Jingran Ji